These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 32690263)
41. Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C. Zhu M; Zhou H; Ma L; Dong B; Ding J; Zhou J; Wang J; Zhang G; Wang M; Shan Q; Cen S; Wang Y Eur J Med Chem; 2022 Apr; 233():114251. PubMed ID: 35278855 [TBL] [Abstract][Full Text] [Related]
42. Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex. Ghosh AK; Brindisi M; Nyalapatla PR; Takayama J; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H Bioorg Med Chem; 2017 Oct; 25(19):5114-5127. PubMed ID: 28434781 [TBL] [Abstract][Full Text] [Related]
43. Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation. Ghosh AK; Yashchuk S; Mizuno A; Chakraborty N; Agniswamy J; Wang YF; Aoki M; Gomez PM; Amano M; Weber IT; Mitsuya H ChemMedChem; 2015 Jan; 10(1):107-15. PubMed ID: 25336073 [TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2-ligand: Structure-activity studies and biological evaluation. Bai X; Yang Z; Zhu M; Dong B; Zhou L; Zhang G; Wang J; Wang Y Eur J Med Chem; 2017 Sep; 137():30-44. PubMed ID: 28554091 [TBL] [Abstract][Full Text] [Related]
45. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies. Ghosh AK; Xia Z; Kovela S; Robinson WL; Johnson ME; Kneller DW; Wang YF; Aoki M; Takamatsu Y; Weber IT; Mitsuya H ChemMedChem; 2019 Nov; 14(21):1863-1872. PubMed ID: 31549492 [TBL] [Abstract][Full Text] [Related]
46. Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. Bulut H; Hattori SI; Aoki-Ogata H; Hayashi H; Das D; Aoki M; Davis DA; Rao KV; Nyalapatla PR; Ghosh AK; Mitsuya H Sci Rep; 2020 Jun; 10(1):10664. PubMed ID: 32606378 [TBL] [Abstract][Full Text] [Related]
47. Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. Ghosh AK; Chapsal BD; Parham GL; Steffey M; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H J Med Chem; 2011 Aug; 54(16):5890-901. PubMed ID: 21800876 [TBL] [Abstract][Full Text] [Related]
48. Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies. Ghosh AK; Williams JN; Ho RY; Simpson HM; Hattori SI; Hayashi H; Agniswamy J; Wang YF; Weber IT; Mitsuya H J Med Chem; 2018 Nov; 61(21):9722-9737. PubMed ID: 30354121 [TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application. Kesteleyn B; Amssoms K; Schepens W; Hache G; Verschueren W; Van De Vreken W; Rombauts K; Meurs G; Sterkens P; Stoops B; Baert L; Austin N; Wegner J; Masungi C; Dierynck I; Lundgren S; Jönsson D; Parkes K; Kalayanov G; Wallberg H; Rosenquist A; Samuelsson B; Van Emelen K; Thuring JW Bioorg Med Chem Lett; 2013 Jan; 23(1):310-7. PubMed ID: 23177258 [TBL] [Abstract][Full Text] [Related]
50. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864 [TBL] [Abstract][Full Text] [Related]
51. Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants. Hattori SI; Hayashi H; Bulut H; Rao KV; Nyalapatla PR; Hasegawa K; Aoki M; Ghosh AK; Mitsuya H Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962341 [TBL] [Abstract][Full Text] [Related]
52. Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors. Nugiel DA; Jacobs K; Kaltenbach RF; Worley T; Patel M; Meyer DT; Jadhav PK; De Lucca GV; Smyser TE; Klabe RM; Bacheler LT; Rayner MM; Seitz SP J Med Chem; 1996 May; 39(11):2156-69. PubMed ID: 8667359 [TBL] [Abstract][Full Text] [Related]
53. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies. Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007 [TBL] [Abstract][Full Text] [Related]
54. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors. Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123 [TBL] [Abstract][Full Text] [Related]